Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Houston, Texas 77030


Purpose:

The goal of this clinical research study is to learn more about the characteristics of CLL, including genes and chromosome abnormalities and proteins expressed by the leukemia cells, which may help doctors predict if patients who receive standard treatment (fludarabine, cyclophosphamide, and rituximab) for the first time will experience a complete remission.


Study summary:

The Study Drugs: Fludarabine is designed to make cancer cells less able to repair damaged DNA (the genetic material of cells). This may increase the likelihood of the cells dying. Cyclophosphamide is designed to interfere with the multiplication of cancer cells, which may slow or stop their growth and spread throughout the body. This may cause the cancer cells to die. Rituximab is designed to attach to lymphoma cells, which may cause them to die. Study Drug Administration: Each cycle is 4-6 weeks. If you are found to be eligible to take part in this study, on Day 1 of each cycle, you will receive rituximab through a needle into your vein over 6-8 hours. On Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond, you will receive fludarabine by vein over 30 minutes. You will also receive cyclophosphamide by vein over 30 minutes. You will receive drugs (such as Tylenol, Benadryl, Zofran, allopurinol, and Valtrex) to help prevent side effects. If you have side effects while receiving rituximab, you may be monitored by the study staff for 2 hours after each dose. Study Visits: Once a week, blood (about 1 tablespoon) will be drawn for routine tests. After 3 months (3 cycles of treatment), the following tests and procedures will be performed: - You will have a physical exam. - Blood (about 2 tablespoons) will be drawn for routine tests. - You will have a bone marrow aspirate and biopsy to check the status of the disease. Length of Study: You will be on treatment for about 6 months. You will be taken off treatment early if you have intolerable side effects or the disease gets worse. End-of-Treatment Visit: After you are off treatment, you will have an end-of-treatment visit for doctors to learn your overall response to the treatment. The following tests and procedures will be performed: - You will have a physical exam. - Blood (about 2 tablespoons) will be drawn for routine tests. - You will have a bone marrow aspirate and biopsy to check the status of the disease. Long-Term Follow-up: At 6 months after you have finished treatment and then every year from then on, you will have follow-up visits. The following tests and procedures will be performed: - You will have a physical exam. - Blood (about 2 tablespoons) will be drawn for routine tests. - If your doctor thinks it is needed, you will have a bone marrow biopsy and aspirate to check the status of the disease. This is an investigational study. Fludarabine, cyclophosphamide, and rituximab are FDA approved and commercially available for the treatment of CLL. The correlation with response to treatment and the characteristics of the leukemia cells is investigational. Up to 300 patients will take part in this study. All will be enrolled at MD Anderson.


Criteria:

Inclusion Criteria: 1. Patients will have a diagnosis of CLL, SLL, or CD20 positive low-grade lymphoproliferative disorder. 2. All patients with untreated Rai stage III-IV are eligible for this protocol. Prior treatment with single-agent rituximab permitted. OR Patients with untreated Rai stage 0-II who meet one or more criteria for active disease as defined by the International Working Group for CLL (IWCLL). Prior treatment with single-agent rituximab permitted. 3. Patients must have an ECOG performance status of 0-3. 4. Patients must have adequate renal and hepatic function (creatinine <2mg%, bilirubin <2mg%). Patients with renal or liver dysfunction due to organ infiltration by lymphocytes may be eligible after discussion with the study chairman. 5. Patients may not receive other concurrent chemotherapy, radiotherapy, or immunotherapy. Localized radiotherapy to an area not compromising bone marrow function does not apply. 6. Patients must be 16 years of age or older. 7. Patients must sign informed consent indicating that they are aware of the investigational nature of this study according to the policies of the MDACC IRB. Exclusion Criteria:


NCT ID:

NCT00759798


Primary Contact:

Principal Investigator
William Wierda, M.D.
M.D. Anderson Cancer Center


Backup Contact:

N/A


Location Contact:

Houston, Texas 77030
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.